US Patent

US10342762 — Small-volume oral transmucosal dosage forms

Formulation · Assigned to AcelRx Pharmaceuticals Inc · Expires 2027-01-05 · 1y remaining

Vulnerability score 60/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects small-volume oral transmucosal dosage forms, specifically NanoTabs, for administering a predetermined amount of a pharmaceutically active drug.

USPTO Abstract

Small-volume oral transmucosal dosage forms or NanoTabs® comprising a predetermined amount of a pharmaceutically active drug are provided. Exemplary applications include use of the NanoTabs® to administer a drug for the treatment of acute, post-operative or breakthrough pain.

Drugs covered by this patent

Patent Metadata

Patent number
US10342762
Jurisdiction
US
Classification
Formulation
Expires
2027-01-05
Drug substance claim
No
Drug product claim
Yes
Assignee
AcelRx Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.